Citation: Jt. Oreilly, IMPLICATIONS OF INTERNATIONAL DRUG APPROVAL SYSTEMS ON CONFIDENTIALITY OF BUSINESS SECRETS IN THE US PHARMACEUTICAL-INDUSTRY, Food and drug law journal, 53(1), 1998, pp. 123-132
Citation: Jt. Oreilly, EXPANDING THE PURPOSE OF FEDERAL RECORDS ACCESS - NEW PRIVATE ENTITLEMENT OR NEW THREAT TO PRIVACY, Administrative law review, 50(2), 1998, pp. 371-389
Citation: Jt. Oreilly, STOP THE WORLD, WE WANT OUR OWN LABELS - TREATIES, STATE VOTER INITIATIVE LAWS, AND FEDERAL PREEMPTION, University of Pennsylvania journal of international economic law, 18(2), 1997, pp. 617-653
Citation: Jt. Oreilly, FDA RULEMAKING AFTER THE 104TH CONGRESS - MAJOR RULES ENTER THE TWILIGHT ZONE OF REVIEW, Food and drug law journal, 51(4), 1996, pp. 677-695
Citation: Jt. Oreilly, RISK ASSESSMENT IN THE 1995 REFORM BILLS - VICTORY FOR BANSHEES, LOSSFOR THE PUBLIC, Administrative law review, 48(3), 1996, pp. 387-397
Citation: Jt. Oreilly, APPLYING FEDERAL OPEN GOVERNMENT LAWS TO CONGRESS - AN EXPLORATIVE ANALYSIS AND PROPOSAL, Harvard journal on legislation, 31(2), 1994, pp. 415-468